MMTN (MNTN) Q1 2026 Earnings Transcript

MNTN reported Q1 revenue of $141.2 million, up 14.3% reported and 12.8% constant currency, while adjusted EBITDA nearly doubled to $17 million and gross margin improved to 81%. Management guided Q2 revenue to $81 million-$83 million and full-year revenue to $347 million-$357 million, implying about 24% growth at the midpoint, with full-year adjusted EBITDA of $96 million-$101 million. The company also highlighted strong customer growth of 46%, accelerated BOX NOAF trial enrollment, and continued momentum from QuickFrame AI and other product launches.

Analysis

MNTN’s setup is less about the headline growth print and more about operating leverage compounding into a higher-quality business model. The key second-order effect is that gross margin expansion is now being driven by structural inputs, not just mix, which means incremental revenue should convert disproportionately into EBITDA if sales efficiency holds. That makes the equity more sensitive to guidance credibility than to the one-quarter beat itself.

The bigger swing factor is the transition from early adopters to mainstream customers. If management is right, agency adoption and new seller coverage create a longer runway, but they also raise execution risk: onboarding friction, longer sales cycles, and potentially higher CAC before retention data fully matures. The market is likely underestimating how much the small-business motion can slow the revenue algorithm if product minimums, approvals, or creative quality become bottlenecks.

Competitive dynamics favor the platform that owns TV-specific performance tooling, not the broadest omnichannel stack. PINS looks like a secondary beneficiary rather than a direct loser: anything that normalizes CTV as a measurable ad budget supports the category, but MNTN’s closed-loop performance and creative automation are harder to replicate than generic demand-side access. The more important risk is not competition today but whether adjacent large platforms decide to subsidize down-market CTV to buy share, compressing pricing power over the next 6-12 months.

For the healthcare side, the accelerated BOX NOAF enrollment is a real catalyst, but the value is mostly optionality until trial completion and readout. The market may be too quick to capitalize that pipeline value into today’s run-rate, so any disappointment in enrollment cadence or commercial launch timing could de-rate the multiple quickly. Near term, this remains a story where evidence generation can move the stock more than quarterly beats.

Key Decisions for Investors

• Long MNTN on pullbacks over the next 2-4 weeks; use any post-earnings consolidation to build exposure for a 3-6 month thesis on operating leverage and product-led share gains. Best risk/reward if the stock can hold above recent support after guidance digestion.
• Buy MNTN upside calls or call spreads into the next 1-2 quarters, targeting a catalyst path from continued margin expansion and BOX NOAF milestone updates. Favor defined-risk structures because multiple expansion, not just fundamentals, is doing the heavy lifting.
• Relative value: long MNTN / short PINS for a 1-3 month trade if you want to express CTV performance monetization without taking broad ad-tech beta. The thesis is that category growth helps both, but MNTN captures more of the direct budget migration and has cleaner operating leverage.
• Avoid chasing after the print; wait for evidence that small-business onboarding and agency scaling do not dilute CAC payback. If customer growth decelerates meaningfully over the next quarter, reduce exposure quickly.
• For healthcare optionality, consider only a small starter long in MNTN ahead of BOX NOAF milestones; size should reflect binary clinical timing risk, with the idea that positive enrollment/readout progress could re-rate the story over 6-12 months.